Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05309382 · ClinicalTrials.gov registry record
Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
A clinical trial of Heart Transplant, sponsored by Natera.
- Completed
- Registry status
- 147
- Enrollment target
- 9
- Study locations
NCT05309382: Completed study of Heart Transplant, sponsored by Natera.
NCT05309382 is a study of Heart Transplant that has completed, run by Natera. The registered enrollment target is 147 participants, below the 8,518-participant average among 12 other Heart Transplant trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05309382, a study of Heart Transplant, has completed, sponsored by Natera.
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a prospective, multicenter observational, unblinded, longitudinal cohort study. Subjects will be enrolled into the study prior to or at the time of heart transplantation. All subjects will follow the center's standard of care surveillance schedule. Blood samples will be collected for Prospera testing at the time any surveillance or for-cause testing, which may include endomyocardial biopsy (EMB), echocardiography or other cardiac imaging studies, and/or molecular testing, is performed.
Primary Outcome
Percent and quantity of donor-derived cell-free DNA (dd-cfDNA) measured via the Prospera test.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prospera
Study Locations (9)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, San Diego - San Diego
Florida
- Mayo Clinic - Jacksonville
Illinois
- Northwestern Memorial Hospital - Chicago
Massachusetts
- Brigham and Women's Hospital - Boston
Ohio
- Cleveland Clinic Foundation - Cleveland
Tennessee
- Vanderbilt University Medical Center - Nashville
Utah
- University of Utah - Salt Lake City
Virginia
- Inova Heart and Vascular Institute - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2024-10-02 |
What the finished NCT05309382 record still lists
NCT05309382 is an observational study that tracks outcomes without assigning an intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 8,518-participant average among 12 other Heart Transplant trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Heart Transplant appearing as the primary indexed condition, and to 1 intervention - of which Prospera is the first listed.
NCT05309382 lists 9 locations in 8 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT05309382 about?
NCT05309382 is a clinical study titled "Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation". This is a prospective, multicenter observational, unblinded, longitudinal cohort study. Subjects will be enrolled into the study prior to or at the time of heart transplantation. All subjects will follow the center's standard of care surveillance schedule. Blood samples will be collected for Prosper...
What is the current status of trial NCT05309382?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2022-12-12. Estimated completion is 2024-10-02.
What conditions does trial NCT05309382 study?
This clinical trial studies the following conditions: Heart Transplant.
What interventions are being tested in trial NCT05309382?
The interventions under investigation include: Prospera (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05309382?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05309382 being conducted?
This trial has 9 study locations across California, Florida, Illinois, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05309382's enrollment target sits among peer trials
147 7th of 12 higher than 6 of 12 other Heart Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
US National OCS Heart Perfusion (OHP) Registry
RECRUITING
-
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
RECRUITING · NA
-
Belatacept in Heart Transplantation
RECRUITING · Phase 2
-
Enhancing Heart Allograft Function With the OCS Heart System Trial
RECRUITING · NA
-
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI